Precision Biosciences Stock Price, News & Analysis

DURHAM, N.C., Jan. 07, 2021 – Precision BioSciences, Inc. (Nasdaq: DTIL) announced the closure of its in vivo gene editing collaboration and exclusive license agreement with Eli Lilly, following regulatory clearance. The collaboration focuses on using Precision's ARCUS genome editing platform for up to six gene targets, including Duchenne muscular dystrophy. Precision receives $100 million upfront and has already received $35 million from share purchases. They are eligible for $420 million in milestones and royalties on product sales. Precision will lead pre-clinical research while Lilly handles clinical development.

Precision BioSciences, a clinical-stage biotechnology company (DTIL), announced that Matt Kane and Derek Jantz will present at the 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021. The company's presentation is scheduled for January 13, 2021, from 2:00 - 2:40 p.m. ET. A live webcast of the event will be available on their website, with an archive accessible for 30 days post-presentation. Precision BioSciences is dedicated to advancing life through its ARCUS® genome editing platform, focusing on CAR T immunotherapy and gene correction therapies.

Precision BioSciences (Nasdaq: DTIL) announced the departure of Chief Financial Officer Abid Ansari after nearly five years, effective at the end of 2020, to pursue a new career opportunity. Alex Kelly, the Chief Corporate Affairs Officer, will serve as Interim CFO, while Shane Barton, Vice President and Corporate Controller, will be the interim principal accounting officer. CEO Matt Kane expressed gratitude for Ansari's contributions during a transformational phase for the company, emphasizing a focus on advancing their allogeneic CAR T cell therapy and in vivo gene correction pipelines.

Precision BioSciences reported encouraging interim clinical results from its Phase 1/2a study of PBCAR0191, an allogeneic CAR T cell therapy targeting CD19. The study enrolled 27 patients, achieving an objective response rate (ORR) of 83% in NHL and B-ALL cohorts, with 75% of NHL patients reaching complete response (CR) by day 28. Enhanced lymphodepletion demonstrated a peak CAR T cell expansion of approximately 95-fold compared to standard methods, with no cases of GvHD or severe CRS. The company plans to advance to its next-generation candidate, PBCAR19B, expected to enter clinical trials in 2021.

DURHAM, N.C., Nov. 24, 2020 - Precision BioSciences, Inc. (Nasdaq: DTIL) announced that its Chief Scientific Officer, Derek Jantz, Ph.D., will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place from November 30 to December 3, 2020. The chat has been pre-recorded and is accessible to registered attendees via the Piper Sandler conference site until December 3. It can also be found on Precision's official website in the Investors and Media section.

Precision BioSciences, Inc. (Nasdaq: DTIL) reported financial results for Q3 2020, showing revenues of $7.4 million, up from $4.9 million in Q3 2019, driven by increased collaboration with Servier. R&D expenses rose to $24.9 million, reflecting ongoing clinical program costs. The net loss widened to $26.0 million, or $(0.50) per share. Key developments included an expanded partnership with Servier for four new CAR T programs and a clinical collaboration for PBCAR269A targeting multiple myeloma. The company expects to report updated interim data from the PBCAR0191 trial by year-end 2020.

Precision BioSciences, Inc. (Nasdaq: DTIL) will report its Q3 2020 financial results and provide a business update on November 10, 2020. The company focuses on its proprietary ARCUS genome editing platform, aiming to treat genetic and infectious diseases through CAR T immunotherapy and in vivo gene correction therapies. Precision BioSciences is dedicated to enhancing therapeutic safety and efficacy, and aims to develop 'off-the-shelf' solutions where current treatments are inadequate.

Precision BioSciences (Nasdaq: DTIL) has received favorable rulings from the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) in two patent interference proceedings, affirming nine patents related to its allogeneic CAR T cell platform. The PTAB dismissed a third party's claim that it invented the technology, allowing Precision’s patents to remain intact. The patented technology allows for consistent and cost-effective CAR T cell production. The patents were issued in 2018 and involve a single-step genome editing process aimed at enhancing cancer immunotherapy.

Precision BioSciences (Nasdaq: DTIL) announced the appointment of Alex Kelly as Chief Corporate Affairs Officer, a newly created role overseeing investor relations and corporate communications. Kelly brings extensive experience from Allergan and other prominent companies, focusing on impactful messaging and business transformations. CEO Matt Kane highlighted Kelly's alignment with the company’s mission in developing innovative CAR T and gene editing therapies. Precision’s pipeline includes multiple CAR T products and gene correction candidates, indicating a significant growth trajectory.